Brian Coleman
Long/short equity, special situations, growth, emerging technology

Compugen: A Wealth Creation Opportunity In The Making

Overview. Over the past three years, using its in-silico discovery platform for predictive drug discovery (i.e. computer models and algorithms), Compugen (NASDAQ:CGEN) has developed a hugely compelling drug Pipeline across several clinical areas with high unmet needs. Compugen's Pipeline includes more than thirty drug candidates in areas with significant interest to large Pharma including cancer immunotherapy, immunology, and its most recently announced discoveries, antibody drug conjugates (ADC).

Despite the company's recent rapid success, and albeit strong stock price performance - up 125% in the past 7 months - its small market cap ($465 million) suggests it still remains well-below the radar of most investors. We think this could change in a very meaningful way as the market comes...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details